-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Today, Dermavant Sciences announced the latest data analysis of tapinarof emulsion in two key phase 3 clinical trials for the treatment of patients with psoriasis.
Psoriasis, also known as psoriasis, is a common chronic, autoimmune inflammatory skin disease.
Tapinarof emulsion is a once-daily aromatic hydrocarbon receptor modulator (TAMA) being developed by Dermavant Sciences for the treatment of plaque psoriasis and atopic dermatitis.
▲The molecular structure of Tapinarof (photo source: Edgar181, Public domain, via Wikimedia Commons)
The results of the trial showed that 18.
"Our key Phase 3 clinical trial results add to the evidence for the effectiveness of tapinarof emulsion and will bring important changes to patients and the doctors who treat them.
Reference materials:
[1] Dermavant to Showcase PASI90, Itch and Quality of Life Data from Phase 3 Pivotal Trials for Tapinarof at AAD VMX 2021.
Note: This article aims to introduce the progress of medical and health research, not to recommend treatment options.